國立虎尾科技大學 |

Modern CNS Drug Discovery = Reinventing the Treatment of Psychiatric and Neurological Disorders /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Modern CNS Drug Discovery / edited by Rudy Schreiber.
其他題名:	Reinventing the Treatment of Psychiatric and Neurological Disorders /
其他作者:	Schreiber, Rudy.
面頁冊數:	XIV, 283 p. 54 illus., 39 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Drug Safety and Pharmacovigilance. -
電子資源:	https://doi.org/10.1007/978-3-030-62351-7
ISBN:	9783030623517

Modern CNS Drug Discovery = Reinventing the Treatment of Psychiatric and Neurological Disorders /
Modern CNS Drug Discovery Reinventing the Treatment of Psychiatric and Neurological Disorders /[electronic resource] :edited by Rudy Schreiber. - 1st ed. 2021. - XIV, 283 p. 54 illus., 39 illus. in color.online resource.

PART I - Introduction -- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist -- PART II - Innovation in the Discovery of Novel Therapeutic Approaches -- Drug Discovery in CNS: Finding a Target for What? -- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity -- Epigenetics in Drug Discovery: Achievements and Challenges -- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation -- Safety and Drug Metabolism: Toward NCE and First in Human -- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance -- Is Non-invasive Brain Stimulation the Low-Hanging Fruit? -- PART III - Translational Medicine and Technology -- Electrophysiology: From Molecule to Cognition, from Animal to Human -- MRI in CNS Drug Development -- Positron Emission Tomography in Drug Development -- Application of Cognitive Test Outcomes for Clinical Drug Development -- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information -- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development -- PART IV - Clinical Development and Regulatory Approval -- The Special Challenges of Developing CNS Drugs -- Phase 1 Clinical Trials in Psychopharmacology -- Early Development of Erenumab for Migraine Prophylaxis -- Microdosing Psychedelics as a Promising New Pharmacotherapeutic -- Partnering with the FDA.

This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the generation of ideas for the identification of targets and novel treatment strategies; covers core functions in early discovery, and provides an example of a novel treatment paradigm: brain stimulation. The third section highlights strategies and technologies in translational CNS drug discovery. In an effort to bridge the gap between discovery and clinical development, it also covers brain imaging, EEG and cognitive testing approaches. The fourth section extensively discusses the clinical phase of drug development, covering the basics of early clinical testing for psychopharmacological drugs. The book’s final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery. Offering in-depth insights into the world of drug development, it represents essential reading for early researchers who want to prepare for a career in drug discovery in academia or industry.

ISBN: 9783030623517

Standard No.: 10.1007/978-3-030-62351-7doiSubjects--Topical Terms:

1064651
Drug Safety and Pharmacovigilance.

LC Class. No.: RC321-580

Dewey Class. No.: 612.8

Modern CNS Drug Discovery = Reinventing the Treatment of Psychiatric and Neurological Disorders /
LDR:04483nam a22003975i 4500 001 1055576
003 DE-He213
005 20210909012039.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030623517 $9 978-3-030-62351-7
024 7 $a 10.1007/978-3-030-62351-7 $2 doi
035 $a 978-3-030-62351-7
050 4 $a RC321-580
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 612.8 $2 23
245 1 0 $a Modern CNS Drug Discovery $h [electronic resource] : $b Reinventing the Treatment of Psychiatric and Neurological Disorders / $c edited by Rudy Schreiber.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XIV, 283 p. 54 illus., 39 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a PART I - Introduction -- Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist -- PART II - Innovation in the Discovery of Novel Therapeutic Approaches -- Drug Discovery in CNS: Finding a Target for What? -- Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity -- Epigenetics in Drug Discovery: Achievements and Challenges -- Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation -- Safety and Drug Metabolism: Toward NCE and First in Human -- The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance -- Is Non-invasive Brain Stimulation the Low-Hanging Fruit? -- PART III - Translational Medicine and Technology -- Electrophysiology: From Molecule to Cognition, from Animal to Human -- MRI in CNS Drug Development -- Positron Emission Tomography in Drug Development -- Application of Cognitive Test Outcomes for Clinical Drug Development -- Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information -- A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development -- PART IV - Clinical Development and Regulatory Approval -- The Special Challenges of Developing CNS Drugs -- Phase 1 Clinical Trials in Psychopharmacology -- Early Development of Erenumab for Migraine Prophylaxis -- Microdosing Psychedelics as a Promising New Pharmacotherapeutic -- Partnering with the FDA.
520 $a This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the generation of ideas for the identification of targets and novel treatment strategies; covers core functions in early discovery, and provides an example of a novel treatment paradigm: brain stimulation. The third section highlights strategies and technologies in translational CNS drug discovery. In an effort to bridge the gap between discovery and clinical development, it also covers brain imaging, EEG and cognitive testing approaches. The fourth section extensively discusses the clinical phase of drug development, covering the basics of early clinical testing for psychopharmacological drugs. The book’s final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery. Offering in-depth insights into the world of drug development, it represents essential reading for early researchers who want to prepare for a career in drug discovery in academia or industry.
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 0 $a Pharmacy. $3 582411
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Neurosciences. $3 593561
700 1 $a Schreiber, Rudy. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1360794
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030623500
776 0 8 $i Printed edition: $z 9783030623524
776 0 8 $i Printed edition: $z 9783030623531
856 4 0 $u https://doi.org/10.1007/978-3-030-62351-7
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)